ACELYRIN(US:SLRN) GlobeNewswire News Roomยท2025-02-06 21:15Core Insights - Alumis Inc. and ACELYRIN, INC. have announced a definitive merger agreement in an all-stock transaction, combining their resources and pipelines to enhance their capabilities in developing therapies for immune-mediated diseases [2][3] Financial Position - As of December 31, 2024, Alumis and ACELYRIN had cash, cash equivalents, and marketable securities of approximately $289 million and $448 million respectively, leading to a pro forma cash position of approximately $737 million, which is expected to provide runway into 2027 [3][4] Pipeline Development - The combined company will focus on advancing a differentiated late-stage portfolio, including Alumis' ESK-001 and ACELYRIN's lonigutamab, with multiple clinical readouts expected in 2025 and 2026 [3][4][11] - ESK-001 is currently in Phase 3 ONWARD trials for moderate-to-severe plaque psoriasis, with topline data expected in the first half of 2026, and Phase 2b LUMUS trial data for systemic lupus erythematosus anticipated in 2026 [11] Merger Details - Under the merger agreement, ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock owned, resulting in Alumis stockholders owning approximately 55% and ACELYRIN stockholders owning approximately 45% of the combined company on a fully diluted basis [7][10] - The transaction is expected to close in the second quarter of 2025, pending stockholder approvals and customary closing conditions [10] Leadership and Structure - The combined company will operate under the Alumis name, led by the current Alumis executive team, with key members from ACELYRIN's team ensuring continuity in the development of lonigutamab [8][9] Strategic Goals - The merger aims to optimize the development of lonigutamab and leverage combined development and commercial expertise to enhance long-term stockholder value [3][6]